Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline

Hagens Berman has filed a securities class action lawsuit against Aardvark Therapeutics, alleging the company made materially false statements about the safety of its lead drug candidate ARD-101. The lawsuit covers investors who purchased stock during the IPO on February 13, 2025, through May 14, 2026. Aardvark voluntarily paused its Phase 3 HERO trial in February 2026 after discovering reversible cardiac observations, causing a 56% stock decline. The FDA subsequently placed a full clinical hold on ARD-101 in May 2026, resulting in an additional 32.1% stock drop. The lead plaintiff deadline is October 13, 2026.